2025 Glooko Annual Diabetes Report

The Glooko 2025 Global Diabetes Report offers a comprehensive look at how real-world data can drive better outcomes in diabetes care. Powered by billions of data points across 30+ countries, this report uncovers meaningful trends in glycemic management, technology adoption, and behaviors among people living with Type 1, Type 2, and gestational diabetes.

From the rise of remote monitoring to the impact of advanced technologies like Continuous Glucose Monitors (CGMs) and Automated Insulin Delivery (AID) systems, this report explores how personalized insights can be used to better inform personalized care, predict risk, and guide clinical decision-making.

Whether you’re a clinician, researcher, or innovator in diabetes management technology, this report highlights how data can be turned into action — helping to shape a smarter, more connected future of diabetes management.

Download the report

Glooko and Abbott FreeStyle Libre CGMs in the United States

At Glooko, we are committed to simplifying diabetes insights and management for people living with diabetes and healthcare providers alike. That’s why our platform is compatible with more than 200 diabetes and health monitoring devices and growing.

As a company, we could not be more pleased to share that we recently expanded our capabilities to integrate with Abbott’s FreeStyle Libre CGMs in the United States. This integration brings glucose data to more clinics and health systems in our all-in-one solutions for diabetes management.

This milestone is more than just a technological advancement — it’s about empowering people with Type 1, Type 2, and gestational diabetes, as well as prediabetes, to become active owners in their health. By combining the precision of Abbott’s FreeStyle Libre CGMs with Glooko’s comprehensive platform, we can provide people living with diabetes and their care teams, including endocrinologists and nurses, with a unified, holistic view of diabetes management and irrefutable information.

TFrom glucose trends to lifestyle behaviors like diet and physical activity, this latest integration ensures that critical insights are easily accessible when and where they are needed most. For healthcare providers and health systems, this means the ability to seamlessly access and analyze patients’ CGM data through Glooko and established electronic health record (EHR) solutions, more informed decision-making, and improved patient outcomes. For people living with diabetes, it means greater confidence in their care and health.

As the number of people with diabetes continues to grow, the need for seamless, data-driven solutions has never been greater. Our new integration with Abbott’s FreeStyle Libre CGMs represents a significant step forward in delivering better, more connected care. This partnership is sure to have a positive impact on the millions of people who rely on FreeStyle Libre CGMs and Glooko.

Glooko and Abbott FreeStyle Libre CGMs in the United States

Diabetes Week UK

In the United Kingdom, diabetes technology has rapidly advanced over the past two decades, with platforms like Glooko playing a central role in simplifying care and management.

In honor of Diabetes Week U.K. (9 June to 15), we’re taking a look at the state of diabetes, technology designed to better manage the condition, and the outlook on the evolution of diabetes care and technology.

The State of Diabetes in the United Kingdom

Diabetes Week UK and GlookoDiabetes is a significant public health concern in the U.K. According to Diabetes U.K., more than 5.8 million people are currently living with the condition. Of these, approximately 4.6 million have been diagnosed and an estimated 1.3 million people may be living with undiagnosed Type 2 diabetes.

Of those diagnosed with diabetes in the U.K., Type 2 diabetes accounts for approximately 90% of cases. While risk factors for Type 1 diabetes include family history and the presence of other autoimmune conditions, Type 2 diabetes risk is heightened obesity, family history, a history of gestational diabetes, specific medications, and other factors.

To address the growing prevalence of diabetes and support those affected, the National Health Service (NHS) offers various education programs aimed at empowering individuals with the knowledge and skills necessary to manage their diabetes effectively, improve health outcomes, and reduce the risk of complications.

For individuals with Type 2 diabetes, programs like DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) and the X-PERT Diabetes Programme provide education on managing the condition through lifestyle changes and self-monitoring. For those with Type 1 diabetes, the DAFNE (Dose Adjustment For Normal Eating) program offers guidance on insulin management and dietary considerations and Digibete helps young people, families, and communities better manage Type 1 diabetes. Additionally, the VICTOR program is designed for adults with Type 2 diabetes who are on insulin therapy and focuses on adjusting insulin doses in response to routine changes.

Diabetes Technology Today

In the U.K., diabetes technology is advancing quickly with Glooko helping streamline data management across compatible diabetes and health monitoring devices, including:

Transforming Diabetes Care in the United Kingdom with Glooko

Diabetes Week UK and Glooko

Across the country, more than 85,000 people living with diabetes use Glooko’s digital health platform to manage their diabetes and more than 500 clinics are using Glooko to provide better care to their patients.*

Through our data*, we identified key metrics for time in range for people with Type 1, Type 2, and gestational diabetes in the U.K. using Glooko during 2024.

Type

Time In Range (TIR) | 3.9-10 mmol/l

Time in Tight Range (TITR) | 3.9-7.8 mmol/l

Type 1 Diabetes

64%

41%

Type 2 Diabetes

58%

34%

Gestational Diabetes

74%

50%

Today, there is an increased interest in TITR and TIR as a result of the recent technology available for managing diabetes. The Glooko diabetes data management platform helps healthcare providers monitor TIR and TITR to improve glycemic outcomes for people living with diabetes, bringing data from multiple devices into one platform with comprehensive charts and graphs. It ensures consistent data access — even without connected devices — and meets high standards for data protection, including GDPR compliance, to support safe, effective, and standardised diabetes care.

The Future of Diabetes Care in the United Kingdom

The future of diabetes care in the U.K. lies in advancing technology and deeper collaboration. Recent key developments include moving towards fully closed loop systems, integrating AI-enabled personalized insights, and aligning diabetes management with weight loss medications. Continued innovation will help provide more tailored, effective treatment options for people living with diabetes.

Progress also depends on strong partnerships with leading diabetes organisations like the Diabetes Technology Network (DTN-UK) and Diabetes National Networking Forums (NNF).

The future of diabetes care in the U.K. lies in advancing technology and deeper collaboration. Recent key developments include moving towards fully closed loop systems, integrating AI-enabled personalized insights, and aligning diabetes management with weight loss medications. Continued innovation will help provide more tailored, effective treatment options for people living with diabetes.

Academy Program with GlookoBy showcasing technologies such as hybrid closed loop systems at local events from these leading organisations and through initiatives like our Academy program, a collaboration between Glooko and the Association of British Clinical Diabetologists(ABCD)/DTN-UK providing free education for medical professionals in the U.K., we help educate, support, and empower both clinicians and people living with diabetes across the country.

*Internal Glooko data; based on active Glooko users that synced during 2024

Glooko Web 25.1 and Mobile 6.11

As part of our ongoing commitment to supporting healthcare providers and people living with diabetes, we’re excited to share the latest enhancements and features now available in Glooko Web 25.1 and Mobile 6.11. These updates are designed to streamline workflows, improve patient engagement and security, and provide care teams with more robust tools to manage diabetes care effectively.

Patient Notes and Medications in Week View

Care teams and people living with diabetes can now view notes and medication entries added to the Glooko Mobile and Web App directly in Week View, both online and in PDF reports. These entries appear in a new collapsible “Events” section below each day, making it easier to contextualize trends in glucose data and treatment behaviors.

Glooko Web 25.1 and Mobile 6.11

Streamlined Week View PDF Reports

In our new release, Week View PDFs are now cleaner and more efficient. Sections without data will be automatically hidden, allowing more patient data over a few days to fit on each page.

The glucose and statistics sections will always remain, and a single, comprehensive legend will now appear at the end of the report.

Smarter Defaults in the PDF Wizard for Hybrid Closed Loop Systems

Designed to streamline reporting workflows and help care teams quickly access the most meaningful insights, the Glooko PDF Wizard now automatically pre-selects the most relevant reports, including Summary, Week, Daily, and Devices, when a patient uses a Hybrid Closed Loop System like Omnipod® 5, Tandem t:slim X2 with Control-IQ technology, or mylife Loop powered by CamAPS® FX.

Care teams can still customize the selections as needed.

Glooko Web 25.1 and Mobile 6.11Enhanced Security in the Glooko Mobile App

At Glooko, we’re committed to the security and safety of our platform users.

People living with diabetes, including those under age 18, can now manage their login credentials (email and password) through a new Login Security section in the Glooko Mobile App’s Account Settings. We’ve also expanded support for two-factor authentication (2FA) to users to ensure an extra layer of protection.

Explore More Updates

For more detailed information about the new features designed to simplify diabetes management, be sure to check out the full release notes on the Glooko Support Center.

Future of Glooko Diabetes Management

Mark Clements, MD, PhD, Chief Medical and Strategy Officer, Glooko

As healthcare providers, we find ourselves at a pivotal moment in diabetes management. Technological advances — from remote patient monitoring to artificial intelligence — have dramatically reshaped patient care. Yet, amid these innovations, a crucial element often remains overlooked: the voices of clinicians and people with diabetes.

In my new expanded role as Chief Medical and Strategy Officer at Glooko, I am excited about the opportunity to transition from direct patient care into a broader role where I can continue to make a significant impact on diabetes management and improve the lives of people with diabetes. I believe my firsthand clinical experience positions me uniquely to guide Glooko’s innovation efforts, ensuring we build tools that genuinely meet the needs of clinicians and people with diabetes alike.

Glooko CGM for DiabetesIn my nearly two decades as a pediatric endocrinologist, I’ve observed the profound potential—and the challenges—of integrating digital solutions into daily diabetes management. Clinicians routinely manage a complex array of tasks: reviewing glucose data from continuous glucose monitors (CGMs) or meters, adjusting insulin regimens, coaching patients on lifestyle, documenting clinical decisions, and coordinating across care teams. With a single person’s CGM device generating up to 288 data points per day, 1 clinicians managing numerous people with diabetes face overwhelming workloads.

Individuals with diabetes echo similar concerns. Many describe data fatigue from constant management and analysis of their glucose levels. As one person stated, “The data is overwhelming; without clear insights and simpler ways to interpret it, it’s just noise.”

Although this wealth of data is invaluable, it contributes significantly to clinician burnout, and burn out among people with diabetes. Alarmingly, half to two-thirds of clinicians experience burnout, driven largely by bureaucratic tasks, extended working hours, and the sheer volume of data management.2,3

Individuals with diabetes also report significant stress from managing their condition daily. Every glucose reading can feel like a pass or fail test. Effective technological integration could alleviate such emotional burdens by making data actionable, intuitive, and less intrusive.

At Glooko, we recognize that technology alone is not sufficient—it must seamlessly integrate into clinician workflows. Clinicians offer essential insights into behaviors of individuals, adherence barriers, and preferences. Unfortunately, many digital diabetes solutions miss the mark due to inadequate clinician input, leading to underutilization—only about 40% see active clinical use.4 Glooko addresses this by ensuring clinician insights directly shape our technology, streamlining workflow integration through interoperability with electronic health records (EHRs).

In a similar vein, simplicity and intuitive user experiences are paramount for people with diabetes to properly leverage diabetes management technologies. If the technology is complicated, it just becomes another barrier.

Today, our connected care platform exemplifies this integrated approach, merging patient-generated data with clinical decision-making tools. Evidence demonstrates connected care significantly improves diabetes outcomes, with reductions in HbA1c levels of up to 1.5% and fewer hypoglycemic events.5 Glooko enables clinicians to swiftly identify high-risk trends and proactively manage care for people with diabetes.

Tomorrow, AI-driven predictive analytics within Glooko could transform diabetes management by forecasting hypoglycemic and hyperglycemic events, facilitating timely, preventive interventions. Automating routine data analysis tasks can reduce clinicians’ documentation burdens by approximately 30%,6,7 significantly alleviating stress and freeing clinicians to focus more deeply on clinical interactions. For people with diabetes, this can provide a significant improvement in their overall diabetes management.

I believe Glooko has immense potential, especially through advanced analytics and decision support. For instance, we could empower clinicians to shift from generalized treatment plans to highly personalized management strategies, grounded in timely data.

Innovation that is guided by those on the frontlines of care — people with diabetes and their care providers — is critical for meaningful advancements that can truly move the needle in diabetes care. In my role, I am dedicated to ensuring our solutions enhance workflows, support better outcomes, and ultimately bring a human-centric approach to diabetes management.

Together, we will define the future of diabetes care, directly addressing challenges clinicians face and improving the lives of those we treat. Here’s to a bright future ahead!

1. Speakman, ASHP. 2. Hammes et al., Endocrine News; Medscape Endocrinologist Lifestyle Report, 2022. 3. Batta et al., BMJ Open Diabetes Res Care. 4. Shah et al., J. Diabetes Sci Technol., 2023.5. Su et al., J. Med Internet Res., 2023. 6. AMA Digital Health Report. 7. Sidharthan et al., Scientific Reports, 2025.

Glooko EHR Integrations

 

At Glooko, we empower healthcare providers with the tools and insights they need to make informed decisions quickly and easily to improve the health outcomes of their patients living with diabetes.

With nearly half of physicians reporting at least one burnout symptom in a recent study from the American Medical Association, it’s critical we make diabetes data management simpler to not overburden those providing care.

That’s why the Glooko platform integrates with leading electronic health record (EHR) systems in the U.S., including Epic, Oracle Health, MEDITECH, Greenway Health, eClinicalWorks, NextGen, and AthenaHealth, making our diabetes management platform seamlessly and securely available within this critical healthcare technology and eliminating the need to platform switch.

Why EHR Integrations Matter

Glooko EHR Integrations

Diabetes care is complex, and healthcare providers face the challenge of managing patient data across multiple systems. In an era where time is precious and clinicians are already spending much of their time on administrative tasks, clinicians need timely access to the most relevant health data without the inefficiencies of navigating multiple data platforms.

By integrating Glooko into EHRs, we streamline how healthcare providers access diabetes data, enabling them to provide the highest quality care. Our integrations provide clinicians and care teams with immediate access to comprehensive data from more than 200 diabetes and health monitoring devices used by their patients, eliminating the need for additional logins and manual data entry by people living with diabetes each day.

EHR integrations not only optimize existing systems, but they also have the potential to enhance clinical decision-making by giving clinicians the full picture of a person’s health. It empowers them to make faster, more informed treatment decisions. That’s why health systems spend $2.5 million to $1.2 billion on EHR integrations each year. They’re powerful and their care teams can reap the benefits of reduced documentation burden.

How It Works

By leveraging SMART on FHIR technology and HL7, standard interoperability frameworks, Glooko integrates with existing EHR systems at hospitals and health systems. Healthcare providers can then access patients’ timely glucose data, medication logs, activity levels, food intake, and much more without leaving the EHR.

The integrations support healthcare systems by offering a single, unified view of a person’s diabetes information, all while ensuring secure, HIPAA-compliant data exchange. The technology is designed to streamline workflows, making it easier for clinicians to focus on what truly matters: providing quality care for their patients.

Glooko EHR Integrations

A Step Toward the Future of Diabetes Care

Following the COVID-19 pandemic, clinical teams who provide care to the more than 38 million people in the U.S. living with diabetes have greatly declined in number, furthering the urgent need for seamless, data-driven solutions to help reduce administrative burdens and workloads that drive burnout.

And the burnout by clinicians and care teams is only going to grow greater as 98 million American adults have prediabetes, according to the CDC.

By optimizing and integrating with leading EHR systems, Glooko is taking a significant step forward in transforming diabetes management and reducing extra steps taken by healthcare providers to improve the quality of care. Our integrations help improve workflows, limit platform switching, simplify clinical decision-making, and support better outcomes for both healthcare providers and people with diabetes.

These integrations represent our ongoing commitment to delivering cutting-edge, interoperable solutions that empower both clinical teams and patients in making diabetes easier to manage.

Ready to Learn More?

Healthcare providers and hospital systems can access EHR integrations by reaching out to our dedicated team for a demo. With robust support from our dedicated team, some integrations, like with Epic, can be up and running within a weeks, making it easier than ever to take advantage of the benefits Glooko has to offer.

To learn more about Glooko’s many EHR integrations, visit our Integration Portal.

Glooko's Mike Alvarez

Glooko CEO Mike AlvarezOver the past several months since stepping into the role of CEO at Glooko, I’ve been reflecting on the incredible progress we’ve made, and the immense opportunities that lie ahead. Each day has reaffirmed my belief that our mission to transform diabetes care is both urgent and achievable. I’m more energized than ever to guide Glooko toward a future where we deliver an even greater impact for people with diabetes and those who care for them.

When I think about the future of diabetes care, one word comes to mind: transformation. Across the globe, health systems, clinicians, and people living with diabetes are looking for a holistic approach, one that brings together cutting-edge technology, patient-centric insights, and secure, scalable solutions. At Glooko, we’ve made it our mission to deliver exactly that.

Our Vision: Transforming Diabetes Care

We believe in transforming diabetes care by making it simpler, more connected, and fundamentally centered on people with diabetes. This vision underpins every decision we make, whether we’re enhancing our platform’s EHR integration, partnering with global device manufacturers, or expanding our footprint in new markets.

Our Mission: Simplifying Care and Strengthening Connections

At Glooko, we say: “We simplify care, strengthen connections, and together create a brighter future for people living with diabetes, healthcare providers, and caregivers.”

Simplify Care

We hear time and again about fragmented workflows and siloed data, forcing providers and patients to juggle multiple device platforms (mobile and web), apps, and logins. Our platform intends to change this, meaning clinicians can potentially spend less time on administrative tasks and more time where they’re needed most: caring for patients and focused on improving outcomes.

Strengthen Connections

We also see the power of community and shared decision-making. Through Glooko, patients, caregivers, and healthcare teams can collaborate more effectively, share real-time data, and gain insights that drive meaningful change in care plans. We aim to reduce the cognitive burden of diabetes data and decision making.

In my view, these are the five biggest differentiators that make Glooko stand out:

  1. Patient First Mindset: Everything we do revolves around putting patients first. We collaborate closely with clinicians, caregivers, and people living with diabetes to ensure our technology meets real-world needs.
  2. Commitment to Quality and Security: From ISO 27001 to HiTrust and SOC 2 Type 2 certifications, our platform is backed by enterprise-grade security and rigorously tested reliability. We understand that healthcare data is precious and that trust is earned through quality.
  3. Innovation That Matters: Our platform is more than a “data upload tool.” It’s an engine designed to support clinical decision making. Whether it’s EHR interoperability or automated patient nudges, we constantly push boundaries to develop meaningful solutions that scale globally.
  4. High-Performance Culture: Within the company, we’re building a talented, global team that challenges the status quo. This energy fuels our drive to expand into new markets, partner with industry leaders, and improve access to diabetes care around the world.
  5. Better Together: Collaboration is in our DNA, and that includes partnerships with device manufacturers, healthcare providers and hospital systems. By joining forces with stakeholders across the healthcare ecosystem, we have the opportunity to create value that benefits everyone, especially people living with diabetes.

Scaling for the Future

Our work has already touched millions of lives, but we’re just getting started. With rising rates of diabetes worldwide, the need for an integrated, secure, and human-centered solution has never been greater. That’s why we’re investing in global expansion, forging new alliances, and refining our platform to make sense of the high volume of data in diabetes care.

Scaling effectively also means staying true to our roots. Our commitment to patient outcomes, uncompromising quality, and secure innovation will remain the bedrock of Glooko’s growth. As we continue to expand, our North Star will always be the same: transforming diabetes care on a global scale and making diabetes easier to manage for everyone in the diabetes care ecosystem.

A Commitment to People Living with Diabetes, Above All

Behind every data point or device upload is a person managing a complex, life-altering condition. We never lose sight of that human element. As Glooko grows, our Patients First value continues to guide us toward solutions that truly make a difference, reducing clinical burdens, improving outcomes, and helping people with diabetes live fuller, healthier lives.

MKT-0532 01

Glooko at ADCES23

​​If you’re planning to attend the Association of Diabetes Care & Education Specialists’ ADCES23 in Houston, Team Glooko wants to meet you at booth #1101 to share the latest updates to our digital health technologies.

​​Some of the exciting activities that you can expect from us at the meeting:

    1. Product Demos: We’ll provide live demos of the recently redesigned Glooko® Mobile App, available now in the App Store and Google Play Store. The sleek, new design improves onboarding for patients with diabetes and makes it even easier for them to input, view and understand their health data.
    2. Ask An Expert: Our booth will host experienced clinicians who will share how their clinics and patients are benefitting from Glooko’s connected care platforms and achieving better health outcomes. Experts at these informal sessions include:
      • Gary Scheiner, MS, CDCES, Integrated Diabetes Services (Friday: 9 to 10 a.m.; Saturday: 11:30 a.m. to 12:30 p.m.) He will cover data analysis and interpretation for a variety of devices, including CGMs, insulin pumps and AID systems. Gary will walk through the various Glooko reports he relies on for different patients and the insights they provide.
      • Susan Weiner, RDN, CDCES, Susan Weiner Nutrition (Friday: 11:30 a.m. to 12:30 p.m.; Saturday: 9 to 10 a.m.) She will review how best to support patients in their self-care by leveraging and incorporating Glooko into their daily lives. She’ll also review various functionalities within the Glooko Mobile App and what she likes most about them from a patient engagement and user experience standpoint.
      • Allison Nimlos, LMFT, CDCES, Greater Than Counseling & Coaching (Saturday: 2:30 to 3:30 p.m.) She will focus on the psychosocial aspects of diabetes care management, including how data can be both empowering and anxiety inducing. Allison will discuss how she onboards newly diagnosed patients by leveraging the app’s different data visualization tools to best support the patient’s mental well-being and desired behavioral changes.
      • Bridget Wood, RD, LD, CDCES, Glooko (Friday: 10 to 11:30 a.m.; Sunday: 9 to 11 a.m.) She will discuss how she uses Glooko as a person living with Type I diabetes. Bridget will also share how to enhance a virtual diabetes coaching practice using the health data in the Glooko Mobile App from both the provider and patient experiences.
    3. Glooko App's Food TrackerFood Tracker: People with diabetes can use the innovative food tracker feature of the Glooko® Mobile App to easily log their food intake, view their food data alongside data from compatible diabetes and health monitoring devices, medications and insulin, and keep a historical account of how food affects their chronic condition.

​​Be sure to also check out our blog series from Glooko’s very own experts.

See you in Houston!

MKT-0479 01

Glooko at the American Diabetes Association's 83rd Scientific Sessions

​​Team Glooko at the American Diabetes Association's 83rd Scientific SessionsAt the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego, Team Glooko was thrilled to connect with so many old and new friends on the tradeshow floor and during industry events.

​​During the conference, our team showcased how our innovative connected care platforms for people living with diabetes and their healthcare providers improve health outcomes. We also provided live demos of the Glooko® Mobile App, which has a sleek new design that makes diabetes management even easier. The redesign boasts improved patient onboarding and streamlined data visualizations that allow for easy inputting, viewing and understanding of health data.

Glooko Product Demo at the American Diabetes Association's 83rd Scientific SessionsAt our booth, we hosted “Ask an Expert” where leading clinicians, including University of Missouri-Kansas City School of Medicine’s Mark Clements, MD PhD CPI FAAP, Cleveland Clinic’s Dr. M. Cecilia Lansang, Rady Children’s Hospital’s Dr. Carla Demeterco-Berggren and Integrated Diabetes Services’ Gary Scheiner, shared how their clinics and patients benefit from the Glooko connected care platforms. The expert clinicians also discussed Glooko’s EHR integration, patient engagement, remote care and population health capabilities with attendees.

Representatives from Dexcom, one of our many device partners, visited our booth to share how their continuous glucose monitors (CGMs) work with our platform for improved diabetes management.

On the tradeshow floor, our team talked with some users of our connected care platforms to hear how Glooko has positively impacted their clinics. Here’s what they said:

Team Glooko at the 2023 DiabetesMine #DData ExChangeWe were also a proud sponsor of the sold-out Summer 2023 DiabetesMine D-Data ExChange, where we held live demos of Glooko. The event was packed with informative and inspiring discussions on the latest developments in diabetes technology.

We look forward to showcasing our latest digital health innovations next year at ADA 2024 in Orlando!

MKT-0473 01

Glooko at ATTD 2023

Glooko at ATTD 2023At the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) in Berlin, Team Glooko had the exciting opportunity to meet new and old friends on the tradeshow floor and offer live demonstrations of the innovative Glooko and Glooko XT connected care platforms at our stand.

And the conference was all about our partnerships with leading global diabetes companies.

Glooko and Dexcom at ATTD 2023We hosted Dexcom, Novo Nordisk and Tandem in our stand to demonstrate how the Glooko platform works with their products for people living with diabetes and their care teams. We also joined these three industry partners in their stands to demonstrate how the Glooko connected care platform works with their digital health innovations and devices.

Glooko and Sanofi at ATTD 2023We announced our new partnership with Sanofi, which gives people with diabetes more choices in customizing their diabetes management by integrating the SoloSmart® cap for SoloStar® insulin pens with the Glooko connected care platform. This new integration will help improve insulin management and tracking, while supporting insulin dosing data.

While we already support an extensive and growing list of diabetes and health monitoring devices, Team Glooko met with over 45 of our partners to discuss how to bring more digital health solutions to healthcare providers.

Our poster presentation, “Remote Patient Monitoring and Glycemic Control Trends During the COVID-19 Pandemic,” highlighted the effectiveness of our remote care platform’s capabilities when healthcare delivery needed to rapidly shift due to stay-at-home orders, but clinicians needed to remain engaged and provide care to their patients with diabetes.

Glooko and diaTribe Foundation at ATTD 2023We were also a proud sponsor of the diaTribe Foundation and ATTD’s panel discussion, “Solvable Problems in Diabetes,” with leading experts around continuous glucose monitoring, time in range and associated therapeutic and data-driven interventions for people living with diabetes.

After an action-packed few days, our team is already looking forward to showcasing our latest innovations next year at ATTD 2024 in Florence.

MKT-0429 01